Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause

Now Viewing

EP: 1.Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause

EP: 2.Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment

EP: 3.Aligning With 2023 ESC Guidelines in oHCM Treatment

EP: 4.Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes

EP: 5.Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice

1. The treatment of obstructive hypertrophic cardiomyopathy (oHCM) has a high level of unmet needs, can you discuss these with us?

• How do novel cardiac myosin inhibitors (CMIs) target the underlying cause of oHCM?

2. What has the impact of CMI’s been on the management of oHCM?

• Complements (first line) standard of care
• Addresses the root cause of oHCM
• Narrowing the substantial gap between effective medical therapy and the more definitive invasive treatments like alcohol septal ablation and surgical myectomy.